Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.21) by 60.38 percent. This is a 17.07 percent increase over losses of $(0.41) per share from the same period last year. The company reported quarterly sales of $139.000 thousand which missed the analyst consensus estimate of $284.000 thousand by 51.06 percent. This is a 20.87 percent increase over sales of $115.000 thousand the same period last year.